Investor Overview

Latest News Releases

2022 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)

Change
Volume
52 Week High
52 Week Low

03/31/23 11:42 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date	Form	Description	Filing Group	View
05/19/23	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-031107.pdf 0001209191-23-031107.rtf 0001209191-23-031107.xls
05/19/23	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-031105.pdf 0001209191-23-031105.rtf 0001209191-23-031105.xls
05/19/23	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-031111.pdf 0001209191-23-031111.rtf 0001209191-23-031111.xls

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report